{
    "organizations": [],
    "uuid": "5b61bf3e63c81da251c260bc42a734353e5cd292",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lidds-successfully-completes-nanoz/brief-lidds-successfully-completes-nanozolid-study-idUSFWN1P50DI",
    "ord_in_thread": 0,
    "title": "BRIEF-LIDDS Successfully Completes NanoZolid Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - LIDDS AB:\n* REG-LIDDS: NANOZOLID® WITH IMMUNE-STIMULATING AGENT CONFIRMS EFFICACY IN AN ADDITIONAL CANCER MODEL\n* SAYS ‍CLEAR ANTI-TUMOR EFFECTS HAVE BEEN OBSERVED IN ANOTHER CANCER MODEL IN MICE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-10T22:09:00.000+02:00",
    "crawled": "2018-01-11T12:21:24.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "lidds",
        "ab",
        "agent",
        "confirms",
        "efficacy",
        "additional",
        "cancer",
        "model",
        "say",
        "effect",
        "observed",
        "another",
        "cancer",
        "model",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}